On May 7, 2024, Lucien Selce announced that he has engaged with Aurinia Pharmaceuticals Inc, stating that 1) the Board severely mishandled the communication of its dead-end strategic review, which resulted in investors fleeing the stock, 2) the Board currently has an excessive number of directors who lack relevant skills and much-needed objectivity, compromising its efficiency and effectiveness, 3) the Board has failed to effectively oversee Peter Greenleaf and a value-enhancing strategy for the Company, 4) the Board has rewarded Greenleaf with RSUs despite lackluster performance, and Peter Greenleaf be removed from the Board to ensure boardroom independence. In addition, Lucien Selce stated that the Board should 1) restructure the Board and reduce its size from 9 directors to 5 directors, 2) link management?s compensation to fulfilling quantitative revenue goals set by an independent Board, 3) develop accretive strategic partnerships.